



May 21, 2026

David Lieber, MD  
Blessing Corporate Services, Inc.

Dear Investigator,

SUBJECT: Notice of IBC Evaluation of Potential Research Modification

**Sponsor: Ferring Pharmaceuticals A/S**  
**Protocol: 000423 (ABLE-32) (ADSTILADRIN)**

Document Evaluated: • Prescribing Information, dated 03-2026

An IBC Chair has determined that the changes in this document do not constitute a modification of the research per the NIH Guidelines, Section IV-B-7-a-(1). Further IBC review is not required before implementing these changes.

Please keep this notification for your records. Note that this document may have been previously reviewed and approved at a convened IBC meeting. For any questions or concerns, please contact WCG IBC Services at (360) 252-2850, or [ibcservices@wcgclinical.com](mailto:ibcservices@wcgclinical.com).

If you have changes to your research to submit, please complete an [IBC Change in Research Form](#), and submit the completed form to [ibcservices@wcgclinical.com](mailto:ibcservices@wcgclinical.com).

cc: Kiley McGlauchlen, MS, CCRP, Blessing Corporate Services, Inc.  
Tim Tranor, Blessing Corporate Services, Inc.  
Ashley Chbeir, Blessing Corporate Services, Inc.  
Eric Martin, Blessing Corporate Services, Inc.  
Spencer Kalk, Syneos Health  
Amanda Carver, Syneos Health  
Katie Robb, Syneos Health  
Daniella Yoon, Syneos Health  
Andy Walden, Syneos Health  
Betsey Kapoor, Syneos Health  
Natalie Amaral, Syneos Health  
Manny Carmona, Syneos Health  
Mykyta Kuzmin, Syneos Health  
Silvia Sanchez MHA, Syneos Health  
Study File